株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中外製薬の製品パイプライン分析

Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 251653
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.98円で換算しております。
Back to Top
中外製薬の製品パイプライン分析 Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
出版日: 2016年07月27日 ページ情報: 英文 119 Pages
概要

中外製薬は日本に本社をおく製薬企業で、ファーマシューティカル製品の開発および商品化を行っています。対象疾患分野は癌、骨および関節の疾患、腎臓疾患等です。同社はバイオ製薬と分子標的薬に関する先進技術を利用し、創薬および薬剤候補物質の開発を行っています。

当レポートでは、中外製薬 における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

中外製薬 の基本情報

  • 中外製薬 の概要
  • 主要情報
  • 企業情報

中外製薬 :R&Dの概要

  • 主な治療範囲

中外製薬 :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

中外製薬 :パイプライン製品の概況

  • 後期段階のパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階のパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

中外製薬:薬剤プロファイル

  • ibandronate sodium
  • atezolizumab
  • gantenerumab
  • lebrikizumab
  • obinutuzumab
  • pertuzumab
  • SA-237
  • tocilizumab
  • trastuzumab emtansine
  • basimglurant
  • bevacizumab
  • codrituzumab
  • nemolizumab
  • pictilisib
  • polatuzumab vedotin
  • RG-1577
  • RG-1662
  • RG-7304
  • taselisib
  • Antibody for Colorectal Cancer
  • CH-5036249
  • CH-5164840
  • CH-5449302
  • CH-5451098
  • cVE-199
  • maxacalcitol
  • Monoclonal Antibody for Hepatitis C
  • NA-255
  • PCO-371

中外製薬 :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

中外製薬 :最新のパイプライン情報

中外製薬 :開発休止中のプロジェクト

中外製薬 :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル

中外製薬 :企業理念

中外製薬 :本社と子会社の所在地

  • 本社

付録

図表一覧

目次
Product Code: GMDHC08098CDB

Summary:

Global Markets Direct's, 'Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review, 2016', provides an overview of the Chugai Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chugai Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Chugai Pharmaceutical Co., Ltd.
  • The report provides overview of Chugai Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Chugai Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Chugai Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Chugai Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chugai Pharmaceutical Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chugai Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Chugai Pharmaceutical Co., Ltd. Snapshot
    • Chugai Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Chugai Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Chugai Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Chugai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Chugai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Chugai Pharmaceutical Co., Ltd. - Drug Profiles
    • atezolizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eldecalcitol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gantenerumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lebrikizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • obinutuzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SA-237
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tocilizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • codrituzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nemolizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • basmisanil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EOS-789
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PCO-371
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polatuzumab vedotin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-7304
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • taselisib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5036249
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5164840
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5449302
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CH-5451098
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CVE-199
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ERY-974
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • maxacalcitol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NA-255
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gMSC-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • Chugai Pharmaceutical Co., Ltd. - Dormant Projects
  • Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • nitazoxanide
      • basimglurant
      • bevacizumab
      • hyaluronate sodium
      • NA-808
      • onartuzumab
      • orlistat
      • PA-799
      • parsatuzumab
      • pictilisib
      • RG-7167
      • sembragiline
      • tocilizumab
      • trastuzumab emtansine
  • Chugai Pharmaceutical Co., Ltd. - Company Statement
  • Chugai Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Chugai Pharmaceutical Co., Ltd., Key Information
  • Chugai Pharmaceutical Co., Ltd., Key Facts
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Chugai Pharmaceutical Co., Ltd. - Phase III, 2016
  • Chugai Pharmaceutical Co., Ltd. - Phase II, 2016
  • Chugai Pharmaceutical Co., Ltd. - Phase I, 2016
  • Chugai Pharmaceutical Co., Ltd. - Preclinical, 2016
  • Chugai Pharmaceutical Co., Ltd. - Discovery, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2016
  • Chugai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
  • Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016
  • Chugai Pharmaceutical Co., Ltd., Other Locations
  • Chugai Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top